Overview

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Status:
COMPLETED
Trial end date:
2025-07-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca